JAK1 and prostate carcinoma: Premature terminating mutations (frameshift and nonsense) in JAK1 were enriched in endometrial cancers (8.2%), prostate cancers (2.7%), urinary cancers (1.2%), and several gastrointestinal tract cancers (gastric, small intestine, and colorectal; <1%, Fig 1D).